Percentage of Claims Accepted by Public Drug Programs for Generic Drugs

Name	Percentage of Claims Accepted by Public Drug Programs for Generic Drugs
Short/Other Names	Not applicable
Description	The rate of claims accepted by public drug programs for generic drugs
Interpretation	This indicator is interpreted as the proportion of utilization that generic drug products account for within public drug programs.
HSP Framework Dimension	Health System Inputs and Characteristics: Efficient allocation of resources
Areas of Need	Not applicable
Geographic Coverage	Newfoundland and Labrador, Prince Edward Island, New Brunswick, Nova Scotia, Ontario, Manitoba, Saskatchewan, Alberta, British Columbia
Reporting Level/Disaggregation	Province/Territory
Indicator Results	https://secure.cihi.ca/estore/productSeries.htm?pc=PCC1011

Identifying Information
Name	Percentage of Claims Accepted by Public Drug Programs for Generic Drugs
Short/Other Names	Not applicable
Indicator Description and Calculation
Description	The rate of claims accepted by public drug programs for generic drugs
Calculation: Description	The total number of claims accepted by public drug programs for generic drugs divided by the total number of claims accepted by public drug programs Unit of Analysis: Claims to public drug programs
Calculation: Geographic Assignment	Place of residence
Calculation: Type of Measurement	Percentage or proportion
Calculation: Adjustment Applied	None
Calculation: Method of Adjustment	Not applicable
Denominator	Description: Total number of claims made to public drug programs Inclusions: All claims accepted by public drug programs Exclusions: Any claims not submitted to or accepted by public drug programs, including claims submitted to a private insurer or cases where the individual pays out of pocket
Numerator	Description: Total number of claims made to public drug programs for a generic drug product Inclusions: All claims for generic drugs accepted by public drug programs Exclusions: 1. Any claims not submitted to or accepted by public drug programs, including claims submitted to a private insurer or cases where the individual pays out of pocket 2. Claims for brand name products
Background, Interpretation and Benchmarks
Rationale	This indicator measures the uptake of generic drugs on public drug programs. Generic drug products are typically less expensive than brand name products.
Interpretation	This indicator is interpreted as the proportion of utilization that generic drug products account for within public drug programs.
HSP Framework Dimension	Health System Inputs and Characteristics: Efficient allocation of resources
Areas of Need	Not applicable
Targets/Benchmarks	Not applicable
References	Not applicable
Availability of Data Sources and Results
Data Sources	NPDUIS Database
Available Data Years	Type of Year: Calendar First Available Year: 2000 Last Available Year: 2014
Geographic Coverage	Newfoundland and Labrador, Prince Edward Island, New Brunswick, Nova Scotia, Ontario, Manitoba, Saskatchewan, Alberta, British Columbia
Reporting Level/Disaggregation	Province/Territory
Result Updates
Update Frequency	Whenever required for analytical product or data request
Indicator Results	Web Tool: Prescribed Drug Spending in Canada URL: https://secure.cihi.ca/estore/productSeries.htm?pc=PCC1011
Updates	Not applicable
Quality Statement
Caveats and Limitations	– Includes only drugs claimed through public drug programs – Excludes any drugs claimed through a private drug plan or purchased over the counter
Trending Issues	All data is not available for all years: – Manitoba, Saskatchewan, Alberta, New Brunswick: From January 2000 – Nova Scotia: From April 2001 – Prince Edward Island: From April 2004 – British Columbia: From January 2006 – Newfoundland and Labrador: From April 2008 – Ontario: From April 2010 – First Nations and Inuit Health Branch: From October 2010
Comments	Not applicable